nach oben

Erschienen in:

21.08.2018 | Oncology

⁶⁸Ga-PSMA-PET/CT in comparison with ¹⁸F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study

verfasst von: Eva Dyrberg, Helle W. Hendel, Tri Hien Viet Huynh, Tobias Wirenfeldt Klausen, Vibeke B. Løgager, Claus Madsen, Erik M. Pedersen, Maria Pedersen, Henrik S. Thomsen

Erschienen in: European Radiology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine the diagnostic accuracy of ⁶⁸gallium prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in comparison with ¹⁸F-fluoride-based PET/CT (NaF-PET/CT) and whole-body magnetic resonance imaging (WB-MRI) for the detection of bone metastases in patients with prostate cancer.

Methods

Sixty patients with prostate cancer were included in the period May 2016 to June 2017. The participants underwent three scans (index tests) within 30 days: a NaF-PET/CT, a WB-MRI and a PSMA-PET/CT. Experienced specialists assessed the scans. In the absence of a histological reference standard, the final diagnosis was determined as a panel diagnosis. Measures of the diagnostic performances of the index tests were calculated from patient-based dichotomous outcomes (0 or ≥ 1 bone metastasis) and pairwise compared (McNemar test). For each index test, the agreement with the final diagnosis with regard to the number of bone metastases detected (0, 1–5, > 5) and the inter-reader agreement was calculated (kappa coefficients).

Results

Fifty-five patients constituted the final study population; 20 patients (36%) were classified as having bone metastatic disease as their final diagnosis. The patient-based diagnostic performances were (sensitivity, specificity, overall accuracy) PSMA-PET/CT (100%, 100%, 100%), NaF-PET/CT (95%, 97%, 96%) and WB-MRI (80%, 83%, 82%). The overall accuracy of PSMA-PET/CT was significantly more favourable compared to WB-MRI (p = 0.004), but not to NaF-PET/CT (p = 0.48). PSMA-PET/CT classified the number of bone metastases reliably compared to the final diagnosis (kappa coefficient 0.97) and with an “almost perfect” inter-reader agreement (kappa coefficient 0.93).

Conclusions

The overall accuracy of PSMA-PET/CT was significantly more advantageous compared to WB-MRI, but not to NaF-PET/CT.

Key Points

• PSMA-PET/CT assessed the presence of bone metastases correctly in all 55 patients

• PSMA-PET/CT was more advantageous compared to WB-MRI

• No difference was found between PSMA-PET/CT and NaF-PET/CT

Nur mit Berechtigung zugänglich

Herrera FG, Tawadros T, Berthold DR (2015) Bone cancer. Primary bone cancers and metastases, 2nd edn. Elsevier, San Diego

Thurairaja R, Mcfarlane J, Traill Z, Persad R (2004) State-of-the-art approaches to detecting early bone metastatic spread and changes to bone biology in prostate cancer. BJU Int 94:268–271CrossRefPubMed

Moulopoulos LA, Koutoulidis V (2015) Bone marrow MRI, 1st edn. Springer-Verlag Italia, Milan

Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609–2617CrossRefPubMed

Elgazaar A (2006) The pathophysiologic basis of nuclear medicine, 2nd edn. Springer, Berlin HeidelbergCrossRef

Høilund-Carlsen PF, Hess S, Alavi A (2017) Bone marrow and NOT bone metastases is what 21st century diagnostic imaging must focus upon when looking for skeletal metastases. J Nucl Med. https://doi.org/10.2967/jnumed.117.201848

Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629CrossRefPubMed

Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate cancer, version 1.2016. J Natl Compr Canc Netw 14:19–30CrossRefPubMed

Fogelman I, Blake GM, Cook GJR (2013) The isotope bone scan: we can do better. Eur J Nucl Med Mol Imaging 40:1139–1140CrossRefPubMed

10.

Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178–211CrossRefPubMed

11.

Bertoldo F, Boccardo F, Bombardieri E et al (2017) Bone metastases from prostate cancer, 1st edn. Springer, ChamCrossRef

12.

Eiber M, Fendler WP, Rowe SP et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58:67S–76SCrossRefPubMed

13.

Hofman MS, Hicks RJ, Maurer T, Eiber M (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38:200–217CrossRefPubMed

14.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85

15.

Evangelista L, Briganti A, Fanti S et al (2016) New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70:161–175CrossRefPubMed

16.

Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ (2017) ⁶⁸ Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging. https://doi.org/10.1111/cpf.12480

17.

Tateishi U, Morita S, Taguri M et al (2010) A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 24:523–531CrossRefPubMed

18.

Pasoglou V, Michoux N, Larbi A, Van Nieuwenhove S, Lecouvet F (2018) Whole body MRI and oncology: recent major advances. Br J Radiol. https://doi.org/10.1259/bjr.20170664%0A

19.

Tombal B, Lecouvet F (2012) Modern detection of prostate cancer’s bone metastasis: is the bone scan era over? Adv Urol. https://doi.org/10.1155/2012/893193

20.

Padhani AR, Koh D-M, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718CrossRefPubMed

21.

Bossuyt PM, Reitsma JB, Bruns DE et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 277:826–832CrossRefPubMed

22.

Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed

23.

Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:887–897CrossRefPubMed

24.

Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209CrossRefPubMed

25.

Morigi JJ, Stricker P, Van Leeuwen P et al (2015) Prospective comparison of the detection rate of 18F-fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy. J Nucl Med 56:1185–1191CrossRefPubMed

26.

Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284–1294CrossRefPubMed

27.

Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674CrossRefPubMed

28.

Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and ⁶⁸Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43:2114–2121CrossRefPubMed

29.

Janssen J, Meißner S, Woythal N et al (2018) Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. Eur Radiol 28:610–619CrossRefPubMed

30.

Evangelista L, Bertoldo F, Boccardo F et al (2016) Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging 43:1546–1562CrossRefPubMed

31.

Woo S, Suh CH, Kim SY et al (2018) Diagnostic performance of magnetic resonance imaging for the detection of bone metastasis in prostate cancer: a systematic review and meta-analysis. Eur Urol 73:81–91CrossRefPubMed

32.

Wondergem M, van der Zant FM, van der Ploeg T, Knol RJJ (2013) A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 34:935–945CrossRefPubMed

33.

Luzzati A, Scotto G, Perrucchini G, Zoccali C (2017) Surgery: treatment of oligometastatic disease. In: Bertoldo F, Boccardo F, Bombardieri E et al (eds) Bone metastases from prostate cancer, 1st edn. Springer, Cham, pp 147–161CrossRef

34.

Avuzzi B, Valdagni R (2017) Bone metastases from prostate cancer: radiotherapy. In: Bertoldo F, Boccardo F, Bombardieri E et al (eds) Bone metastases from prostate cancer, 1st edn. Springer, Cham, pp 163–180CrossRef

35.

Fendler WP, Calais J, Allen-Auerbach M et al (2017) ⁶⁸Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med 58:1617–1623CrossRefPubMed

36.

Mannweiler S, Amersdorfer P, Trajanoski S et al (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167–172CrossRefPubMed

37.

Fendler WP, Eiber M, Beheshti M et al (2017) ⁶⁸Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014–1024

38.

Giesel FL, Hadaschik B, Cardinale J et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688CrossRefPubMed

39.

Ceci F, Castellucci P, Cerci JJ, Fanti S (2017) New aspects of molecular imaging in prostate cancer. Methods 130:36–41CrossRefPubMed

40.

Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92CrossRefPubMedPubMedCentral

41.

Beheshti M, Vali R, Waldenberger P et al (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35:1766–1774CrossRefPubMed

42.

McCarthy M, Siew T, Campbell A et al (2011) ¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38:14–22

43.

Garcia JR, Moreno C, Valls E et al (2015) Diagnostic performance of bone scintigraphy and 11C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 34:155–161PubMed

44.

Fonager RF, Zacho HD, Langkilde NC et al (2017) Diagnostic test accuracy study of 18F-sodium fluoride PET/CT, 99mTc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. Am J Nucl Med Mol Imaging 7:218–227PubMedPubMedCentral

45.

Jambor I, Kuisma A, Ramadan S et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55:59–67CrossRefPubMed

Titel: 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study
verfasst von: Eva Dyrberg
Helle W. Hendel
Tri Hien Viet Huynh
Tobias Wirenfeldt Klausen
Vibeke B. Løgager
Claus Madsen
Erik M. Pedersen
Maria Pedersen
Henrik S. Thomsen
Publikationsdatum: 21.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 3/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5682-x

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

⁶⁸Ga-PSMA-PET/CT in comparison with ¹⁸F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

C-Arm computed tomography (CACT)-guided balloon pulmonary angioplasty (BPA): Evaluation of patient safety and peri- and post-procedural complications

Imaging of pulmonary perfusion using subtraction CT angiography is feasible in clinical practice

Transcatheter aortic valve replacement alters ascending aortic blood flow and wall shear stress patterns: A 4D flow MRI comparison with age-matched, elderly controls

MR imaging based fractal analysis for differentiating primary CNS lymphoma and glioblastoma

Accessory cavitated uterine mass: MRI features and surgical correlations of a rare but under-recognised entity

Automated MR-based lung volume segmentation in population-based whole-body MR imaging: correlation with clinical characteristics, pulmonary function testing and obstructive lung disease

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie